Drug Profile
Research programme: glucagon-like peptide-1 receptor modulators - Axxam/Spexis
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Axxam; Polyphor
- Developer Axxam; Spexis
- Class
- Mechanism of Action Glucagon-like peptide 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in Italy
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in Switzerland
- 27 Jul 2011 Early research in Type-2 diabetes mellitus in Italy (unspecified route)